Campaign Unavailable

We're sorry, this alert is no longer available. If you would like to learn more about ways you can take action, please visit AIDS Healthcare Foundation.

The short explanation of this alert was:

Indian generic drug manufacturer, Cipla, sells their lifesaving second-line anti-retroviral treatment drug, Viraday, at two and half times the price they charge in Africa. When second-line therapy is critically needed in India, Cipla's excessive pricing puts the drug out of reach to their own people.

Cipla's marketing slogan, "None shall be denied" is futile until the price of HV/AIDS drugs is made affordable to the millions of Indians living with HIV/AIDS.

If you would like to view details on this alert, please visit here.